Dr. Ghosh’s multifaceted expertise uniquely positions him at the intersection of clinical medicine, social science, and policy-oriented research. His work underscores the intricate relationship between climate change and health outcomes, a domain that has gained increasing recognition as one of the most pressing public health challenges of our time. His nomination by Dr. Deborah Estrin, a leading computer science professor at Cornell Tech and advocate for interdisciplinary impact, highlights Dr. Ghosh’s exceptional capacity to integrate diverse perspectives into powerful, actionable research.

Following a path less traveled by traditional physicians, Dr. Ghosh combines clinical practice with rigorous scientific inquiry funded by both the National Institutes of Health (NIH) and the National Science Foundation (NSF). His clinical responsibilities at NewYork-Presbyterian/Weill Cornell Medical Center complement his research role in Weill Cornell’s Division of General Internal Medicine. Notably, his previous recognition as an NIH Climate and Health Scholar has deepened his understanding of how environmental factors contribute to health disparities and disease burden, especially among vulnerable populations.

Dr. Ghosh’s research has been profoundly shaped by his direct experience providing care in the aftermath of extreme weather disasters. His involvement in response efforts during the 2009 Australian wildfires, Hurricane Sandy in New York City (2012), and Hurricane Maria in Puerto Rico (2017) exposed him to the disproportionate toll these events exact on marginalized groups. These experiences have informed his focus on how climate-driven disasters exacerbate social inequities and compound health risks for communities often neglected in policy discussions.

At the core of his scientific inquiry lies the development of targeted interventions to mitigate health risks posed by climate phenomena such as heatwaves, hurricanes, intense precipitation, and flooding. These environmental stressors substantially impair air quality, disrupt food supply chains, and challenge public health infrastructure. The epidemiological consequences include exacerbations of cardiovascular and respiratory conditions, heat-related illnesses, and psychological stress, all demanding innovative, evidence-based solutions to reduce morbidity and mortality.

Dr. Ghosh advocates for embedding climate and health considerations into the scientific research agenda and policy frameworks. He stresses that the increasing frequency and intensity of extreme weather events call for urgent, coordinated responses at the national level. Emphasizing the necessity for interdisciplinary approaches, he asserts that solutions must extend beyond medical interventions to encompass socio-environmental determinants and resilient health system design.

In his advisory role at the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, Dr. Ghosh has contributed significantly to the Climate Resilience for Health Care Toolkit. This resource aims to equip healthcare organizations with strategic guidance for emergency preparedness and resilience planning amid escalating climate threats. His frontline perspective underscores concerns about the adequacy of current systems in facing imminent hurricane and heatwave seasons, highlighting urgent gaps in adaptive capacity.

Locally, Dr. Ghosh’s influence extends into the largest county health system in the U.S., Health + Hospitals New York City, where he serves as an Emergency Management Fellow. His expertise informs climate and flood mitigation strategies, reflecting a crucial integration of climate science, urban planning, and public health practice. Moreover, his role on the advisory board for New York City’s Master Urban Forestry Plan demonstrates his commitment to leveraging natural infrastructure—particularly urban tree canopy expansion—to mitigate heat, flooding, and air pollution, with an eye toward environmental justice.

Of particular concern to Dr. Ghosh is the heightened vulnerability of older adults to extreme heat, a demographic trend exacerbated by global warming. He co-leads the Initiative for Extreme Heat and Aging, a multidisciplinary collaboration spanning Cornell and Weill Cornell Medicine. This project seeks to deploy scientifically rigorous, technologically innovative, and justice-centered approaches to protect aging populations from climate hazards. The initiative exemplifies a new paradigm in climate-health research, synergizing biomedical science, technology, and social equity.

Dr. Ghosh’s emphasis on cross-sector collaboration reflects a profound understanding that climate-adaptive health interventions require holistic and systemic solutions. He rejects simplistic, biomedical-only approaches, advocating for multi-dimensional programs that address structural determinants of vulnerability. According to Dr. Ghosh, harnessing the interests and expertise of stakeholders across public health, urban planning, data science, emergency management, and community organizations is essential for scalable and sustainable impact.

As part of his three-year engagement with the National Academy of Medicine’s Emerging Leaders program, Dr. Ghosh will engage with mentors and collaborate on initiatives cutting across a spectrum of disciplines, including pediatrics, psychiatry, infectious diseases, and biomedical engineering. This interdisciplinary network aims to cultivate novel insights and translational strategies to confront evolving health threats linked to environmental change, positioning Dr. Ghosh among a cadre of pioneering scientific leaders.

In summary, Dr. Arnab Ghosh exemplifies the new wave of physician-scientists addressing the climate-health nexus with innovation, urgency, and interdisciplinary collaboration. His work embodies the convergence of clinical insight, public health principles, and environmental science, charting a path toward resilient health systems and equitable interventions in an era of climatic uncertainty. His recognition as an Emerging Leader signalizes not only personal achievement but also the critical importance of integrating climate considerations into the future of health research and policy.

Subject of Research: Climate Change and Health; Climate-Related Health Interventions; Health Equity and Environmental Justice; Emergency Preparedness and Resilience in Healthcare Systems; Aging and Extreme Heat Adaptation.

Article Title: Dr. Arnab Ghosh: Pioneering Climate Resilience in Medicine through Interdisciplinary Leadership

News Publication Date: Not provided

Web References:
https://vivo.weill.cornell.edu/display/cwid-akg9010
https://nam.edu/news-and-insights/nam-announces-10-emerging-leaders-in-health-and-medicine-2025/
https://nam.edu/
https://factor.niehs.nih.gov/2023/12/feature/1-feature-nih-names-climate-and-health-scholars
https://tech.cornell.edu/people/deborah-estrin/
https://extremeheat.us/about/#:~:text=to%20Extreme%20Heat-,The%20Cornell%20Initiative%20on%20Aging%20and%20Adaptation%20to%20Extreme%20Heat,and%20digital%20tools%20as%20levers.

Image Credits: Weill Cornell Medicine

Keywords: Internal medicine, Health care, Natural disasters, Public health

For more than three decades, the National Institutes of Health (NIH) and associated federal bodies have funneled considerable resources into autism spectrum disorder (ASD) research. This long-term investment has yielded profound insights into the genetic, neurological, and environmental factors contributing to autism, confirming the disorder’s complexity and heterogeneity. The coalition’s members highlight key milestones in scientific discovery, including identification of hundreds of genetic variants associated with autism risk, elucidation of neurodevelopmental pathways, and an increasingly nuanced understanding of how gene-environment interactions modulate expression.

Importantly, the coalition expresses deep concern over the dismissal by the HHS secretary of this substantial body of work. His recent remarks reportedly minimize the causal influence of genetics in autism and propagate narratives that contradict both clinical and empirical observations. Such positions, they argue, trivialize decades of research and disrespect the autistic community by perpetuating stigmatizing misconceptions. The scientists emphasize that appreciating the multifactorial basis of autism is essential for formulating meaningful interventions and policies that genuinely support autistic individuals and their families.

The coalition’s statement also calls for transparency and scientific integrity in upcoming research initiatives announced by HHS. Of particular contention is the plan to swiftly execute a study aiming to identify a singular environmental toxin as causative for autism—a move criticized for potentially bypassing established protocols of peer review, open data access, and independent analysis. Since autism’s etiology involves complex gene-environment interplay rather than simple unifactorial causation, the coalition insists that any new study must be grounded in methodological rigor and inclusive scientific scrutiny to prevent misleading conclusions.

Autism research is grounded in decades of methodological evolution, employing a range of sophisticated techniques spanning genomics, neuroimaging, and longitudinal behavioral analyses. The coalition points out that advancements such as genome-wide association studies (GWAS), epigenetic profiling, and high-resolution brain connectivity mapping have collectively revolutionized the field. These technologies have not only illuminated underlying biology but also facilitated the development of targeted interventions that address core symptoms and comorbidities. It is within this framework that future research must progress, rather than circumventing established approaches in favor of expedient but scientifically dubious claims.

Helen Tager-Flusberg elaborates on the coalition’s unified vision, emphasizing that autism research must prioritize unresolved questions that hold translational potential. “Finite resources necessitate focusing on the unknowns rather than rehashing settled issues,” she states. Areas such as the neuroimmune interface, the developmental trajectory of social communication networks in the brain, and heterogeneity in response to interventions represent frontiers that, if effectively explored, could transform clinical practice and improve quality of life for autistic individuals.

Furthermore, the coalition underscores the importance of community engagement and mutual respect between scientists and the public. Trust in biomedical research is paramount, especially within vulnerable populations like those affected by autism. The spread of misinformation and politicization of science raises stakes for public confidence. The coalition advocates for adherence to transparent protocols, robust ethical standards, and participatory models that include autistic individuals and their advocates as stakeholders in research design and dissemination.

The planned HHS study’s expedited timeline raises additional alarms, as it risks oversimplifying complex etiological frameworks into narrow causal assertions. The coalition argues that such an approach could divert precious funding away from longitudinal, multifactorial investigations and marginalize the voices of diverse autism communities whose experiences reflect a broad spectrum of needs. They urge that rigorous peer review and open commentary from the research community and families should guide study protocols before implementation.

Autism spectrum disorder’s prevalence has been increasing globally, a fact extensively documented by epidemiological research. Understanding whether this trend reflects better diagnostic tools, increased awareness, or environmental changes requires meticulous, multi-layered analyses. The coalition points out that attributing rising prevalence rates to a solitary environmental factor, as suggested by the current HHS agenda, ignores years of sophisticated data synthesis and misleads policymakers and the public alike.

In conclusion, the Coalition of Autism Scientists articulates a call to action for the Department of Health and Human Services to reaffirm a commitment to evidence-based research principles. Scientific progress in autism has been hard-won through collaborative, transparent inquiry and must not be undermined by politicized or premature assertions. With collaborative effort and sustained funding, the field is poised to unravel autism’s intricate biological underpinnings and translate discoveries into compassionate, effective support mechanisms for autistic individuals and their families.

As this dialogue continues, the autism research community remains steadfast in upholding scientific rigor as the cornerstone of progress. The coalition’s forthcoming website promises to serve as a resource hub for researchers, practitioners, and the public, facilitating access to data, fostering connections, and promoting informed discourse. Their leadership under Dr. Tager-Flusberg represents a renewed dedication to advancing autism science responsibly, ethically, and inclusively in an era of both unprecedented challenge and opportunity.

Subject of Research: People

Article Title: Coalition of Autism Scientists Critiques U.S. Department of Health and Human Services Autism Research Initiative

News Publication Date: April 25, 2025

Web References: Coalition of Autism Scientists Signatories List

Keywords: Autism; Discovery research; Developmental disabilities; Health and medicine; Scientific approaches

Dr. Cara Gonzales, an assistant professor in the Department of Comprehensive Dentistry at UT Health San Antonio, has established herself at the forefront of cancer research through her company, Keraceuticals, based in San Antonio. Gonzales’s primary focus is on CIDD99, a pioneering drug that targets a unique anti-cancer pathway. The innovation imbued in CIDD99 could represent a transformative approach in treating various aggressive cancer types, offering a potentially effective treatment with significantly fewer adverse side effects when compared to current therapies.

The partnership between UT Health San Antonio and Keraceuticals exemplifies the dynamic synergy of academic and industry collaboration. As research institutions continue to evolve alongside entrepreneurial ventures, such alliances have the potential to catalyze significant advancements in medical science. The innovative approach of CIDD99 is particularly noteworthy as it addresses a previously unexplored pathway that is crucial for the survival of cancer cells, suggesting that it could substantially improve therapeutic options for patients battling severe forms of cancer.

In recent years, the utilization of STTR grants has become pivotal for small businesses and research institutions striving to move scientific breakthroughs from laboratories into practical applications. This specific STTR grant is an outcome of a highly competitive selection, managed by the U.S. Small Business Administration and financed by various partner entities, including the National Institutes of Health’s National Institute of Dental and Craniofacial Research. This partnership is integral for providing essential resources, such as advanced research infrastructure and preclinical development expertise, thereby accelerating the progress of CIDD99 into clinical testing.

Dr. Gonzales’s research program, titled “1,3-Thioureas as First-In-Class Mitochondrial Inhibitors to Treat Oral Cancer,” is innovative in its approach to targeting cancer through a patent-protected compound. The underlying mechanism of CIDD99 offers promise in reducing tumor growth and overcoming the common resistance observed in cancer treatments. By exploring alternative therapeutic paths, Dr. Gonzales and her team under the auspices of UT Health aim to deliver effective and less toxic therapies for patients suffering from various forms of cancer.

Oral squamous cell carcinoma presents an urgent global health concern, being the sixth most frequent cancer diagnosis worldwide and characterized by its dismally low survival rates. Historically, oral squamous cell carcinoma has posed significant challenges in terms of patient prognosis, with current treatments yielding little to no change in survival rates over the past five decades, especially for recurrent forms of the disease. The introduction of targeted therapies like CIDD99 that can directly address the complexity of this cancer type represents a critical shift in treatment modalities, highlighting the importance of ongoing research and development.

The highlights in the development process for CIDD99 are encouraging, showcasing promising preclinical results that indicate substantial tumor growth reduction in mouse models. The findings suggest that the compound’s effectiveness may extend beyond oral cancer, demonstrating potent anti-cancer properties across various other malignancies. This broad applicability underscores the potential for CIDD99 not only to impact oral cancer treatment but also to deliver efficacy in other difficult-to-treat malignancies such as non-small cell lung cancer, breast cancer, and various others.

Dr. Gonzales’s research is a vital intersection of clinical research and development that harnesses the cutting-edge capabilities of UT Health San Antonio. As they strive to bring CIDD99 closer to clinical application, the collaboration embodies a forward-thinking model of innovation. The focus on delivering a new class of cancer therapies could lead to significant advancements in how these diseases are treated, informing better clinical practices and enhancing the quality of life for patients.

The collaborative efforts being made between UT Health San Antonio and Keraceuticals illuminate the essential role such partnerships play in bridging the gap between rigorous academic research and real-world medical applications. By sharing expertise, resources, and a collective vision, they are paving the way for future discoveries in cancer research. Ultimately, this alliance stands to benefit not only those involved in the studies but patients globally who are eager for effective treatment options in battling such formidable illnesses.

As the overarching aim remains clear—to enhance outcomes for patients with aggressive cancers globally—there lies hope in the future development of CIDD99. Through the successful transition from research to clinical applications, the potential exists to break new ground in cancer treatments, signifying a monumental leap forward. Additionally, by addressing the longstanding unmet needs within existing treatment protocols, this research could transform the landscape of cancer treatment and patient care.

Looking towards the future, the collaborative vision shared by Dr. Gonzales and the team at UT Health San Antonio and Keraceuticals illustrates a promising path forward for cancer therapeutics. Each step taken in this journey not only represents hope for those battling cancer but also an inspiring narrative of innovation in translational medicine. As the research unfolds, the anticipation builds around the impact that CIDD99 could have in reshaping the treatment paradigm of oral cancer and beyond, offering renewed optimism in the relentless fight against cancer.

Subject of Research: Development of CIDD99 for Oral Cancer Treatment
Article Title: Collaborative Breakthrough in Cancer Treatment: UT Health San Antonio’s Innovation in Oral Cancer Therapy
News Publication Date: January 30, 2025
Web References: UT Health San Antonio
References: N/A
Image Credits: N/A
Keywords: Oral cancer, Cancer research, Drug development, Scientific collaboration, Drug research